Company Profile

DR. REDDYS LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE3920.951.1 (+0.03 % )
PREV CLOSE (Rs.) 3919.85
OPEN PRICE (Rs.) 3964.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 21816
TODAY'S LOW / HIGH (Rs.)3908.90 3965.70
52 WK LOW / HIGH (Rs.)2352 4189.35
NSE3921.45 0.9 (+0.02 % )
PREV CLOSE(Rs.) 3920.55
OPEN PRICE (Rs.) 3940.00
BID PRICE (QTY) 3921.45 (38 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 456078
TODAY'S LOW / HIGH(Rs.) 3910.00 3967.95
52 WK LOW / HIGH (Rs.)2351.2 4190

Company News

Date Heading Details
02-Jul-2020 Dr. Reddys Laboratories gains as its inks pact with FUJIFILM, Global Response Aid <P align=justify>Dr. Reddys Laboratories is currently trading at Rs. 3916.95, up by 6.35 points or 0.16% from its previous closing of Rs. 3910.60 on the BSE.<BR><P align=justify>The scrip opened at Rs. 3959.00 and has touched a high and low of Rs. 3977.00 and Rs. 3902.00 respectively. So far 13012 shares were traded on the counter.<BR><P align=justify>The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.<BR><P align=justify>Last one week high and low of the scrip stood at Rs. 4064.65 and Rs. 3887.00 respectively. The current market cap of the company is Rs. 65118.26 crore.<BR><P align=justify>The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.<BR><P align=justify>Dr Reddy's Laboratories has partnered with FUJIFILM Corporation through FUJIFILM Toyama Chemical (FUJIFILM) and Global Response Aid (GRA) for the development, manufacture and sales of Avigan Tablets (generic name: favipiravir), a potential treatment of COVID-19.&nbsp; <BR><P align=justify>Under the tripartite agreement signed on June 30, 2020, FUJIFILM grants Dr. Reddy's the exclusive rights of manufacturing and also grants both Dr. Reddy's and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia. The company would have exclusive rights for development, selling and distribution of Avigan in India. Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy's and GRA. The FUJIFILM Group is currently conducting a clinical study on Avigan targeting COVID-19 patients in Japan and the US, and is working to increase the drug's production by partnering with domestic and overseas companies. Dr. Reddy's and GRA shall introduce the product in the market post all applicable approvals in the respective countries.<BR><P align=justify>Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<P align=justify><BR><P align=justify><BR>
01-Jul-2020 Dr Reddy's Laboratories inks pact with FUJIFILM, Global Response Aid <DIV align=justify>Dr Reddy's Laboratories has partnered with FUJIFILM Corporation through FUJIFILM Toyama Chemical (FUJIFILM) and Global Response Aid (GRA) for the development, manufacture and sales of Avigan Tablets (generic name: favipiravir), a potential treatment of COVID-19.&nbsp; </DIV><DIV align=justify>&nbsp;</DIV><DIV align=justify>Under the tripartite agreement signed on June 30, 2020, FUJIFILM grants Dr. Reddy's the exclusive rights of manufacturing and also grants both Dr. Reddy's and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia. The company would have exclusive rights for development, selling and distribution of Avigan in India. Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy's and GRA. The FUJIFILM Group is currently conducting a clinical study on Avigan targeting COVID-19 patients in Japan and the US, and is working to increase the drug's production by partnering with domestic and overseas companies. Dr. Reddy's and GRA shall introduce the product in the market post all applicable approvals in the respective countries.<BR></DIV><DIV align=justify>Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.</DIV><DIV align=justify><BR></DIV>
29-Jun-2020 Dr Reddy's expects to launch 25 products in US market in FY21 <p align="justify">Dr Reddy's Laboratories is expecting to launch 25 products in the US market in the current financial year (FY21). The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year. </p><p align="justify">Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan. And, in parallel, it is working on multiple other biosimilar products, which are at different stage of development.</p><p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<br></p>
29-Jun-2020 Dr Reddy's inches up on expecting to launch 25 products in US market in FY21 <p align="justify">Dr. Reddys Laboratories is currently trading at Rs. 4011.55, up by 15.65 points or 0.39% from its previous closing of Rs. 3995.90 on the BSE.</p><p align="justify">The scrip opened at Rs. 4000.00 and has touched a high and low of Rs. 4018.65 and Rs. 3995.90 respectively. </p><p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 4134.00 and Rs. 3966.75 respectively. The current market cap of the company is Rs. 66419.24 crore.</p><p align="justify">The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.</p><p align="justify">Dr Reddy's Laboratories is expecting to launch 25 products in the US market in the current financial year (FY21). The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year. </p><p align="justify">Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan. And, in parallel, it is working on multiple other biosimilar products, which are at different stage of development.</p><p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas<br></p>
29-Jun-2020 ITI, Mahindra Logistics and Coal India to see some action today <p align="justify"><strong>ITI</strong> and Tech Mahindra have signed a Memorandum of Understanding (MoU) to work together in the areas of 4G &amp; 5G smart networks, Smart Cities and Health Care services, in order to supplement country's requirement of self-reliance in the area of Telecommunication. ITI and Tech Mahindra will collaborate to create ‘Make in India' stack as part of this MoU for the upcoming 4G &amp; 5G opportunities in India. </p><p align="justify"><strong>Mahindra Logistics'</strong> board has approved further investment in Lords Freight (India), subsidiary company by way of purchase of 3,80,970 equity shares of Lords (representing 16.13% of equity share capital of Lords) from the existing promoter shareholders of Lords. Presently, the company holds 82.92% of the share capital of Lords and on completion of the transfer formalities of said 3,80,970 equity shares of Lords, the company's shareholding in Lords would increase by 16.13%. The Investment Committee of the Board of Directors of the company at their Meeting held on June 27, 2020, has approved the same. </p><p align="justify"><strong>Coal India's</strong> subsidiary -- Northern Coalfields (NCL) is looking to pump in Rs 7,000 crore over the next four years to ramp up production capacity and boost infrastructure at various projects. Of this amount, an investment of about Rs 3,000 crore is planned for procurement of heavy earthmoving machines and another Rs 3,000 crore will be used for development of additional coal evacuation-related infrastructure. Around Rs 200 crore will be used in developing 50 MW solar power plant. </p><p align="justify"><strong>Adani Green Energy</strong> has received shareholders' approval to raise Rs 2,500 crore in its fifth annual general meeting held on June 25, 2020. The company also got shareholders' nod to have flexibility to infuse additional capital to tap capital markets and to raise additional long term resources, if necessary, in order to sustain rapid growth in the business, for business expansion and to improve the financial leveraging strength of the firm.</p><p align="justify"><strong>Dr Reddy's Laboratories</strong> is expecting to launch 25 products in the US market in the current financial year (FY21). The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year. Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan. And, in parallel, it is working on multiple other biosimilar products, which are at different stage of development.</p><p align="justify">CA Clover Intermediate II Investments, an affiliated entity of CAP V Mauritius, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc. has agreed to invest fresh equity capital for a 20% stake in <strong>Piramal Enterprises'</strong> wholly owned subsidiary -- Piramal Pharma. The estimated equity capital investment in Piramal Pharma would amount to over Rs 3,700 crore. The final amount of equity investment will depend on the net debt, exchange rate and performance against the pre-agreed conditions at the time of closing of the deal.</p><p align="justify"><strong>IDBI bank</strong> has received an approval to sell its stake held in IDBI Federal Life Insurance Company (IFLI) to the extent of 23% to Ageas and 4% to Federal Bank at a combined value of about Rs 595 crore. The meeting of Board of Directors of the bank held on June 26, 2020, approved the same.<br></p>
23-Jun-2020 Dr. Reddy's Laboratories working on four new products <p align="justify">Dr. Reddy's Laboratories is working on four new products which are in the final stage besides some early stage drugs. The products' segment focuses on research and development, and commercialisation of different formulations. The new compounds are in the therapeutic areas of paediatrics, dermatology, haematology-oncology. <br></p><p align="justify">DFD-11(Xeglyze) in paediatrics area is intended for treatment of head lice in patients six months of age or older. PPC-06 (Tepilamide Fumarate) in dermatologyis for the treatment of plaque psoriasis in patients 18 years of age or older. Compound E7777 is intended to be used in the treatment of Cutaneous T Cell Lymphoma while DFD-29 (Low dose minocycline) is aimed at Papulopustular rosacea. <br></p><p align="justify">As of March 31, 2020, the Company have had four late-stage projects at various stages of development ranging from products that have completed Phase-2 clinical trials to products that are undergoing investigation for US FDA approval. <br></p><p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.</p><p align="justify"><br></p>
19-Jun-2020 Dr. Reddy's launches Abiraterone Acetate Tablets in US market <DIV align=justify>Dr. Reddy's Laboratories has launched Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the US Food &amp; Drug Administration (USFDA). </DIV><DIV align=justify>&nbsp;</DIV><DIV align=justify>The Zytiga brand and generic market had U.S. sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health. The company's Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120. <BR><BR></DIV><DIV align=justify>Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<BR><BR></DIV>
19-Jun-2020 Dr. Reddy's inches up on launching Abiraterone Acetate Tablets in US market <p align="justify">Dr. Reddy's Laboratories is currently trading at Rs. 4008.55, up by 3.80 points or 0.09% from its previous closing of Rs. 4004.75 on the BSE.<p align="justify">The scrip opened at Rs. 4030.00 and has touched a high and low of Rs. 4044.90 and Rs. 3994.00 respectively. So far 14166 shares were traded on the counter.<p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.<p align="justify">Last one week high and low of the scrip stood at Rs. 4127.20 and Rs. 3954.20 respectively. The current market cap of the company is Rs. 66484.06 crore.<p align="justify">The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.<p align="justify">Dr. Reddy's Laboratories has launched Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the US Food &amp; Drug Administration (USFDA).&nbsp;The Zytiga brand and generic market had U.S. sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health. The company's Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120.<p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<p align="justify">&nbsp;</p>
15-Jun-2020 Dr. Reddy's surges on launching Colchicine tablets in US market <p align="justify">Dr. Reddys Laboratories is currently trading at Rs. 4109.00, up by 102.35 points or 2.55% from its previous closing of Rs. 4006.65 on the BSE.</p><p align="justify">The scrip opened at Rs. 4054.00 and has touched a high and low of Rs. 4127.20 and Rs. 4026.00 respectively. So far 10998 shares were traded on the counter.</p><p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 4189.35 and Rs. 3938.90 respectively. The current market cap of the company is Rs. 66579.34 crore.</p><p align="justify">The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.</p><p align="justify">Dr. Reddy's Laboratories along with its subsidiaries have launched Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).</p><p align="justify">The Colcrys brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health. The company's Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s. </p><p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<br></p>
15-Jun-2020 Reliance Industries, Tata Motors and Wipro to see some action today <p align="justify">TPG is planning to invest Rs 4,546.80 crore in Jio Platforms, a wholly-owned subsidiary of <strong>Reliance Industries</strong>, at an equity value of Rs 4.91 lakh crore and an enterprise value of Rs 5.16 lakh crore. The investment will translate into a 0.93% equity stake in Jio Platforms on a fully diluted basis for TPG. With this investment, Jio Platforms has raised Rs 102,432.45 crore from leading global technology investors including Facebook, Silver Lake, Vista Equity Partners, General Atlantic, KKR, Mubadala, ADIA, and TPG since April 22, 2020.</p><p align="justify"><strong>Tata Motors</strong> is buying out its partner Jayem Automotives in their joint venture JT Special Vehicles that develops high-performance vehicles. The company has inked a pact to acquire 50 percent stake of Jayem Automotives in JT Special Vehicles (JTSV). JTSV will become a wholly-owned subsidiary of the auto major after completion of the procedural requirements.</p><p align="justify"><strong>Wipro</strong> has launched its Digital Inspection Solution for improved workplace safety and experience. Powered by IBM's integrated workplace management system (IWMS) IBM TRIRIGA, the solution complements Wipro's existing Engineering NXT portfolio in the digital transformation of business operations. The solution's robust functionality featuring a simple end-user application can manage and complete any type of inspection across mobile phones and tablets with ease. </p><p align="justify"><strong>Vodafone Idea</strong> has begun offering cellular services for Apple Watch (GPS + Cellular), starting with specific circles. The move will give customers the freedom to leave their phone behind and stay connected with just their Apple Watch. This service is available for Vodafone postpaid customers, including enterprise postpaid, in select circles (Mumbai, Delhi and Gujarat) beginning June 12, 2020. The services will continue to be expanded to additional circles in coming weeks. </p><p align="justify"><strong>TCM</strong> has entered into a non-exclusive licensing agreement with Foundation for Innovation and Technology Transfer (FITT), a registered society under the Societies Registration Act 1860, established by the Indian Institute of Technology, Delhi (IIT-Delhi) with respect to KNOWHOW for commercial purpose that includes designing, manufacturing and sales as per the terms and conditions of this agreement of 'Novel Primer set for molecular diagnostic of SARS-CoV-2', that is for the diagnosis of and screening for the COVID-19 using one step RT-qPCR method on all India basis for a period of 5 years effective from June 12, 2020. </p><p align="justify"><strong>GMR Infrastructure's</strong> step down subsidiary -- GMR Visakhapatnam International Airport (GVIAL) has signed the Concession Agreement for the development and operations of Greenfield international airport at Bhogapuram in Andhra Pradesh with the Government of Andhra Pradesh. In April 2020, GMR Airports (GAL) had received the Letter of Award for implementation of project on a PPP basis. The project involves design, build, finance, construction, development, operation and maintenance of Greenfield International Airport at Bhogapuram for the period of 40 years, extendable by additional 20 years through international competitive bidding process, with GMR airports limited having RoFR of 10%.</p><p align="justify"><strong>Dr. Reddy's Laboratories</strong> has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc. (Gilead) that will grant Dr. Reddy's the right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India. The company will receive technology transfer from Gilead for manufacturing of this drug. The company would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries.<br></p>